Submit your Center of Excellence Application today!

Read More


Jan 11, 2019

Statins Cut Retinopathy Risk in Type 2 Diabetes

Statins Cut Retinopathy Risk in Type 2 Diabetes

Regular use in patients with dyslipidemia also decreased progression

by Salynn Boyles, Contributing Writer

Treatment with statins was associated with a significantly decreased risk of diabetic retinopathy in patients with type 2 diabetes and high cholesterol in a large cohort study from Taiwan.

Statin therapy was also associated with a lower need for invasive treatments for vision-threatening diabetic retinopathy, and the benefits of statin treatment were dose dependent.

While several widely reported studies, including ACCORD-EYE, have suggested that statin treatment slows progression of diabetic retinopathy in patients with diabetes and dyslipidemia, the new study, published online in JAMA Ophthalmology, is among the first to assess statin use for the primary prevention of the eye disorder.

Diabetic retinopathy is a leading microvascular complication of diabetes. According to one estimate, as many as 191 million people worldwide will have developed the vision-threatening eye disorder by 2030.

Yih-Shiou Hwang, MD, PhD, of Chang Gung Memorial Hospital in Taoyuan, Taiwan, and colleagues conducted the population-based cohort study using the National Health Insurance Research Database (NHIRD) of longitudinal claims data from medical practices receiving payment from the single-payer Taiwan National Health Insurance.

Of 1,648,305 patients with type 2 diabetes recorded in the database from 1998 through 2013, a total of 219,359 were eligible for the analysis, including 199,760 patients taking statins and 19,599 not taking statins.

After propensity score matching, the analysis included 18,947 patients in the statin group (10,436 women and 8,511 men; mean [SD] age, 61.5 [10.8]) and 18,947 patients in the nonstatin group (10,430 women and 8,517 men; mean [SD] age, 61.0 [11.0]), with a mean follow-up of 7.6 years for the statin group and 7.3 years for the nonstatin group. During the study period, 2,004 patients in the statin group (10.6%) and 2,269 in the non-statin group (12.0%) developed diabetic retinopathy…..

Read more:

Source: Med Page Today




Leave a Reply

Your email address will not be published. Required fields are marked *

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.